Vitamin B1 Market to Reach $528.0 Million by 2035

Vitamin B1 Market was valued at $325.0 million in 2025 and is projected to reach $528.0 million by 2035, growing at a CAGR of 5.0% during the forecast period (2025–2035). The global Vitamin B1 (Thiamine) market is experiencing growth due to increasing health awareness, rising demand for dietary supplements, and the expansion of government-supported food fortification programs aimed at addressing micronutrient deficiencies. A key factor contributing to this growth is the prevalence of thiamine deficiency in certain population groups, which has increased the use of Vitamin B1 in pharmaceutical formulations, fortified foods, and clinical nutrition products. One of the most recognized conditions associated with thiamine deficiency is Wernicke–Korsakoff syndrome, a serious neurological disorder that occurs due to inadequate Vitamin B1 levels. According to the National Library of Medicine, the global prevalence of Wernicke–Korsakoff syndrome is estimated to range between 0% and 2%, with higher rates observed among vulnerable populations such as individuals with chronic alcohol use or severe malnutrition. The need for thiamine replacement therapy in the treatment and management of this disorder continues to support the demand for Vitamin B1 formulations across pharmaceutical and clinical nutrition applications.

Browse the full report description of “Vitamin B1 Market Size, Share & Trends Analysis Report by Type (Thiamine Mononitrate Thiamine Hydrochloride) by Form(Powder, Tablets, Capsules, Liquid) by Application (Animal Feed, Pharmaceuticals, Dietary Supplements, Food & Beverages) by Sales Channels (Direct Sales, Indirect Sales) Forecast Period (2026-2035)” at https://www.omrglobal.com/industry-reports/vitamin-b1-market

Regulatory & Compliance Milestone

The Vitamin B1 sector has entered a new era of oversight in 2024-2025, marked by stringent safety re-evaluations and upgraded manufacturing protocols across major global markets:

• Upgraded Manufacturing Standards (India Schedule M): As of early 2024, the Government of India has mandated a significant upgrade to Good Manufacturing Practices (GMP). This "Schedule M" revision enforces stricter requirements for production plants and equipment, ensuring that Vitamin B1 manufactured in the region meets heightened global quality benchmarks. Furthermore, an Inter-Ministerial Committee recommendation in early 2025 maintains that B1 products with purely nutritional claims will remain under FSSAI oversight, streamlining the pathway for nutraceutical innovation.
• EU Safety & Worker Protection (EFSA 2025): In a comprehensive re-evaluation concluded in March and April 2025, the European Food Safety Authority (EFSA) reaffirmed the safety of thiamine hydrochloride and thiamine mononitrate for all animal species and consumers. However, the update introduces rigorous new worker safety requirements, identifying these compounds as potential skin/eye irritants and respiratory sensitisers, necessitating enhanced protective protocols during the handling and manufacturing phases.
• Tightened Purity & Contaminant Benchmarks: To ensure the integrity of global food fortification, international technical standards (USP/FCC) have been reinforced. Current benchmarks now mandate a strict Purity Assay between 98.0% and 102.0%. Crucially, new thresholds for heavy metal contaminants have been established, limiting lead to 2 ppm and arsenic to 1 ppm, effectively raising the bar for pharmaceutical and food-grade thiamine globally.

Innovation Leaders Transforming the Global Vitamin B1 Market

The key players in the colloidal silicon dioxide market include Brother Enterprises Holding Co., Ltd., dsm-Firmenich., Huazhong Pharmaceutical Co., Ltd., Jiangxi Tianxin Pharmaceutical Co.,Ltd, and Xinfa Pharmaceutical Co., Ltd., among others. These companies are driving innovation in thiamine biosynthesis and advanced nutritional delivery through continuous investments in research, high-purity pharmaceutical-grade formulations, and application-specific solutions for human nutrition, animal feed, clinical therapeutics, and large-scale food fortification programs.

• In January 2026, the New Zealand government pharmaceutical agency PHARMAC announced the approval and funding of a new strength of thiamine hydrochloride (Vitamin B1) injection, 50 mg/mL, for use in public hospitals. The initiative aims to improve treatment accessibility for patients with Vitamin B1 deficiency and related neurological conditions, while ensuring a more stable supply of injectable thiamine products in the healthcare system. The introduction of this new formulation is expected to support clinical treatment efficiency and reduce medicine wastage in hospitals.
• In June 2023, Lupin Limited announced the launch of Thiamine Hydrochloride Injection USP (200 mg/2 mL) in the United States after its alliance partner Caplin Steriles Limited received approval from the U.S. Food and Drug Administration for its Abbreviated New Drug Application (ANDA). The injectable formulation is therapeutically equivalent to the reference listed drug from Fresenius Kabi USA LLC and is used for the treatment of Vitamin B1 (thiamine) deficiency. The launch strengthens Lupin’s injectable pharmaceutical portfolio and supports the growing demand for Vitamin B1-based therapies, particularly in hospital and clinical settings across the United States.

Market Coverage

• The market number available for – 2025-2035
• Base year- 2025
• Forecast period- 2026-2035
• Segment Covered-
  • By Type
  • By Form
  • By Application
  • By Sales Channel
• Regions Covered-
  • North America
  • Europe
  • Asia-Pacific
  • Rest of the World
• Competitive Landscape - Brother Enterprises Holding Co., Ltd., dsm-Firmenich., Huazhong Pharmaceutical Co., Ltd., Jiangxi Tianxin Pharmaceutical Co.,Ltd, and Xinfa Pharmaceutical Co., Ltd., among others.

Key questions addressed by the report.

• What is the market growth rate?
• Which segment and region dominate the market in the base year?
• Which segment and region will project the fastest growth in the market?
• Who is the leader in the market?
• How are players addressing challenges to sustain growth?
• Where is the investment opportunity?

Global Vitamin B1 Market Report Segment

By Type

• Thiamine Mononitrate
• Thiamine Hydrochloride

By Form

• Powder
• Tablets
• Capsules
• Liquid

By Application

• Pharmaceuticals
• Food & Beverages
• Dietary Supplements
• Animal Feed

By Sales Channels

• Direct Sales (B2B)
• Indirect Sales

Global Vitamin B1 Market Report Segment by Region

North America

• United States
• Canada

Europe

• UK
• Germany
• Italy
• Spain
• France
• Russia
• Rest of Europe

Asia-Pacific

• China
• India
• Japan
• South Korea
• Australia and New Zealand
• ASEAN Economies
• Rest of Asia-Pacific

Rest of the World

• Latin America
• Middle East & Africa

To learn more about this report request a sample copy @ https://www.omrglobal.com/request-sample/vitamin-b1-market